公开(公告)号：US20070276140A1

公开(公告)日：2007-11-29

申请号：US10576567

申请日：2004-11-01

Applicant: Christian Wolf ,  Xuefeng Mei

Inventor： Christian Wolf ,  Xuefeng Mei

IPC: C07D219/02

CPC classification number: C07D213/06 ,  C07D213/89 ,  C07D219/02 ,  C07D221/18 ,  C07D307/00 ,  G01N33/52

Abstract: One aspect of the invention relates to 1,8-diarylnaphthalene compounds. In certain embodiments, a compound of the invention is an N-oxide of a 1,8-diarylnaphthalene. In certain embodiments, the aryl group is an optionally substituted acridyl group. In certain embodiments, a compound of the invention is a single steroisomer. In certain embodiments, a compound of the invention is a single enantiomer. Another aspect of the present invention relates to a method of detecting the presence of an analyte in a sample by monitoring the fluorescence of a compound of the invention in a sample. In certain embodiments, the analyte is a metal ion. Another aspect of the present invention relates to a method of determining the enantiomeric purity of an analyte by monitoring the fluorescence of a compound of the invention in the presence of the analyte. In certain embodiments, the analyte is a compound that is capable of hydrogen bonding.

Abstract translation: 本发明的一个方面涉及1,8-二芳基萘化合物。 在某些实施方案中，本发明的化合物是1,8-二芳基萘的N-氧化物。 在某些实施方案中，芳基是任选取代的吖啶基。 在某些实施方案中，本发明的化合物是单一的立体异构体。 在某些实施方案中，本发明的化合物是单一的对映异构体。 本发明的另一方面涉及通过监测样品中本发明化合物的荧光来检测样品中分析物的存在的方法。 在某些实施方案中，分析物是金属离子。 本发明的另一方面涉及通过在分析物的存在下监测本发明化合物的荧光来测定分析物的对映体纯度的方法。 在某些实施方案中，分析物是能够氢键合的化合物。

公开(公告)号：US07888509B2

公开(公告)日：2011-02-15

申请号：US10576567

申请日：2004-11-01

Applicant: Christian Wolf ,  Xuefeng Mei

Inventor： Christian Wolf ,  Xuefeng Mei

IPC: C07D401/02 ,  C07D215/02 ,  C07D217/02

CPC classification number: C07D213/06 ,  C07D213/89 ,  C07D219/02 ,  C07D221/18 ,  C07D307/00 ,  G01N33/52

Abstract: One aspect of the invention relates to 1,8-diarylnaphthalene compounds. In certain embodiments, a compound of the invention is an N-oxide of a 1,8-diarylnaphthalene. In certain embodiments, the aryl group is an optionally substituted acridyl group. In certain embodiments, a compound of the invention is a single steroisomer. In certain embodiments, a compound of the invention is a single enantiomer. Another aspect of the present invention relates to a method of detecting the presence of an analyte in a sample by monitoring the fluorescence of a compound of the invention in a sample. In certain embodiments, the analyte is a metal ion. Another aspect of the present invention relates to a method of determining the enantiomeric purity of an analyte by monitoring the fluorescence of a compound of the invention in the presence of the analyte. In certain embodiments, the analyte is a compound that is capable of hydrogen bonding.

Abstract translation: 本发明的一个方面涉及1,8-二芳基萘化合物。 在某些实施方案中，本发明的化合物是1,8-二芳基萘的N-氧化物。 在某些实施方案中，芳基是任选取代的吖啶基。 在某些实施方案中，本发明的化合物是单一的立体异构体。 在某些实施方案中，本发明的化合物是单一的对映异构体。 本发明的另一方面涉及一种通过监测样品中本发明化合物的荧光来检测样品中分析物的存在的方法。 在某些实施方案中，分析物是金属离子。 本发明的另一方面涉及通过在分析物的存在下监测本发明化合物的荧光来测定分析物的对映体纯度的方法。 在某些实施方案中，分析物是能够氢键合的化合物。

公开(公告)号：US20200181121A1

公开(公告)日：2020-06-11

申请号：US16791916

申请日：2020-02-14

Applicant: Xuefeng Mei ,  Jianrong Wang ,  Qihui Yu

Inventor： Xuefeng Mei ,  Jianrong Wang ,  Qihui Yu

IPC: C07D403/10 ,  C07D285/20

Abstract: The present disclosure relates to a cocrystal of telmisartan and hydrochlorothiazide, a preparation method and use thereof. In the cocrystal, the molar ratio of telmisartan and hydrochlorothiazide is 1:1. The cocrystal of telmisartan and hydrochlorothiazide was characterized by X-ray powder diffraction (XRPD), proton nuclear magnetic resonance spectra (1H-NMR), thermal gravimetric analysis (TG), scanning differential calorimetry (DSC) and infrared (IR) spectra, and it was found that the maximum plasma concentration of the cocrystal in SD rats was higher than that of any one of hydrochlorothiazide and telmisartan itself. The cocrystal of telmisartan and hydrochlorothiazide has a simple preparation method and good physical and chemical properties.